Methods for the estimation of the NICE cost effectiveness threshold

Karl Claxton, Steve Martin, Marta Soares, Nigel Rice, Eldon Spackman, Sebastian Hinde (), Nancy Devlin (), Peter C Smith and Mark Sculpher
Additional contact information
Steve Martin: Department of Economics and Related Studies, University of York, UK
Eldon Spackman: Centre for Health Economics, University of York, UK
Peter C Smith: Imperial College, London, UK

No 081cherp, Working Papers from Centre for Health Economics, University of York

Abstract: A study by health economists at the University of York has, for the first time, produced an estimate of the impact on other NHS patients of new and more costly drugs and other treatments. This research suggests a refinement of the way the National Institute for Health and Clinical Excellence (NICE) gauges the cost-effectiveness of new interventions. It also has implications for the prices that the NHS can afford to pay for new drugs when the value-based pricing scheme for all new drugs is introduced by the Government in 2014.

Keywords: cost-effectiveness (search for similar items in EconPapers)
Pages: 412 pages
Date: 2013-01
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (49)

Downloads: (external link)
http://www.york.ac.uk/media/che/documents/papers/r ... eshold_(Nov2013).pdf First version, 2013 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:chy:respap:81cherp

Access Statistics for this paper

More papers in Working Papers from Centre for Health Economics, University of York Contact information at EDIRC.
Bibliographic data for series maintained by Gill Forder ().